Evidence map›Paper›PMID 30069684›Full record

ArticleCNS drugs2018

Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.

Dimitrios Papadopoulos, Dimos-Dimitrios D Mitsikostas

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in CNS drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Dimitrios PapadopoulosMultiple Sclerosis Centre and Neurology Section, Athens Medical Centre - Paleo Phaliro Clinic, 175-62, Athens, Greece.
Dimos-Dimitrios D Mitsikostas1st Neurology Department, Aeginition Hospital, Medical School, National and Kapodistrian University of Athens, 72-74 V. Sofia's Avenue, 11528, Athens, Greece. dmitsikostas@med.uoa.gr.ORCID http://orcid.org/0000-0002-4691-3388

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe likelihood to help or harm (LHH) is an absolute measure of the benefit versus risk profile of a medication, which can be used to assess the potential for benefit versus harm of different disease-modifying treatments (DMTs) for relapsing multiple sclerosis (R-MS) and facilitate clinical decision-making.

objectiveThe objective of this study was to assess absolute differences in benefit:risk ratios of oral DMTs for R-MS, using LHH analysis with no evidence of disease activity (NEDA) as beneficial outcome. DESIGN/

methodsThe number needed to treat for a paient to achieve NEDA (NNTB

resultsThe values for likelihood to achieve NEDA than experience any AE ratio (LHH

conclusionsWith all of the oral DMTs examined, R-MS patients are more likely to achieve NEDA than experience any adverse event.

Indexed as

AdolescentAdultAgedCladribineClinical Trials, Phase III as TopicCrotonatesDimethyl FumarateDrug-Related Side Effects and Adverse ReactionsFemaleFingolimod HydrochlorideHumansHydroxybutyratesImmunosuppressive AgentsMaleMiddle AgedMultiple SclerosisCladribineCrotonatesDimethyl FumarateFingolimod HydrochlorideHydroxybutyratesImmunosuppressive AgentsNitrilesteriflunomideToluidines

Identifiers

PMID30069684

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.